A study of effects of concomitant administration of proton pump inhibitors (PPIs) and capecitabine (cape) on survival in early stage colorectal cancer (CRC) patients (pts).

Julia Sun,Alastair Ilich,Christina Kim,Michael Patvin Chu,Grace Wong,Sunita Ghosh,Jennifer L. Spratlin,Karen E. Mulder,Melanie Danilak,Carole R Chambers,Michael B. Sawyer

A study of effects of concomitant administration of proton pump inhibitors (PPIs) and capecitabine (cape) on survival in early stage colorectal cancer (CRC) patients (pts).

2015

Julia Sun
Alastair Ilich
Christina Kim
Michael Patvin Chu
Grace Wong
Sunita Ghosh
Jennifer L. Spratlin
Karen E. Mulder
Melanie Danilak
Carole R Chambers
Michael B. Sawyer

e17688 Background: Cape is used to treat CRC and other cancers. Many pts take PPIs for symptom control. TRIO-013, a study of cape/oxaliplatin +/- lapatinib in metastatic gastro-esophageal cancer, f...

Keywords:

Capecitabine
Pathology
Oncology
Colorectal cancer
Internal medicine
Concomitant
Medicine
Lapatinib
Oxaliplatin
symptom control
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations